Big Japanese Pharmas Unlikely To Replace Expiring Patents With M&As
This article was originally published in PharmAsia News
Analysts believe the mergers-and-acquisitions drive of Japan's large drug makers is not likely to fill the void the companies face as their best-selling brands lose patent protection. Several Japanese pharmas have acquired foreign firms to help refill their dwindling portfolios, but analysts say that move is not likely to be enough to keep the companies from falling off what one said was a patent cliff. Drug makers in other countries have faced similar problems over the past 10 years, but this is the first time Japanese pharmas have faced the cliff. So far, Daiichi Sankyo is the only large maker that has not faced the loss of patent protection for a major drug. (Click here for more
You may also be interested in...
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.
Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.
The FDA’s generic drug program yearly performance report shows that generic drug approvals declined for the first time in five years in fiscal year 2020, and the agency also reported a lower number of ANDA submissions.